CRISM Therapeutics (AIM: CRTX) starts ChemoSeed recruitment as first dosing nears

CRISM Therapeutics Corporation (AIM: CRTX) has formally activated the first clinical site for its Phase II study of irinotecan-ChemoSeed in surgically resectable glioblastoma and commenced patient recruitment, moving its lead programme from trial preparation into clinical enrolment. Importantly, recruitment means potential participants can now be identified, screened and enrolled; it does not mean the first patient has already received ChemoSeed.

The registered OPTICAL programme is designed for an estimated 147 participants. Part 1 is a 12-patient, non-randomised dose-escalation study in recurrent glioblastoma intended to establish safety and a recommended Phase II dose. Part 2 is designed to enrol 135 newly diagnosed patients and randomise them 2:1 between ChemoSeed plus standard care and standard care alone.

CRISM has already secured substantial funding for the initial stage. Innovate UK awarded £896,088 under its Biomedical Catalyst programme, covering 70% of the £1.280 million cost of Part 1, while CRISM completed an oversubscribed £2.745 million equity fundraising during May and June.

Why is patient recruitment different from first-patient dosing?

Clinical trial activation is an operational milestone rather than an efficacy result. Once a site is activated, investigators can begin screening patients against eligibility criteria, completing informed consent and scheduling the surgical procedures necessary for treatment. Dosing follows only after an eligible participant is formally enrolled and reaches the intervention stage.

That distinction matters for investors because biotechnology announcements can appear to move programmes further forward than they actually have. CRISM has crossed an important threshold, but the first real human-treatment milestone will be implantation of irinotecan-ChemoSeed in a trial participant.

How does the ChemoSeed approach differ from conventional chemotherapy?

ChemoSeed is designed as a biodegradable implant placed directly into the resection margin after surgical removal of the brain tumour. It releases irinotecan locally over time rather than relying entirely on systemic administration to deliver chemotherapy to the tumour environment.

The scientific rationale is attractive because local delivery could potentially increase drug exposure in the tissue where recurrence occurs while reducing systemic exposure. That remains a hypothesis the clinical programme must test rather than an established patient benefit.

Part 1 is therefore deliberately small. Twelve recurrent glioblastoma patients will help investigators establish tolerability and dosing before CRISM exposes the much larger newly diagnosed population planned for Part 2.

Why does the 12-patient first stage matter so much to a 147-patient programme?

Part 1 determines the maximum tolerated dose and recommended dose that can be carried into the randomised efficacy stage. If safety or dosing problems emerge in those first patients, the design, timing or feasibility of Part 2 could change materially.

Part 2 is where the clinical proposition faces a more rigorous efficacy test. The 135-patient cohort will compare ChemoSeed plus standard treatment against standard treatment alone, with progression-free survival identified as the primary efficacy measure.

The commercial significance of the programme therefore should not be judged from initial recruitment numbers. CRISM must first show the implant can be used safely in the surgical setting before asking whether it improves disease control.

How much financing risk has CRISM removed from the first clinical stage?

Innovate UK is covering 70% of the £1.280 million Part 1 project cost through its £896,088 grant. That leaves CRISM responsible for the remaining 30% of the defined project cost while also funding corporate overhead and other development activities.

The £2.745 million equity raise completed in May and June substantially strengthened the company’s resources relative to its position at the end of 2025. CRISM has stated that it is funded to complete Part 1, materially reducing the immediate risk that this initial clinical stage has to be interrupted by another financing.

That does not mean the entire 147-patient programme is fully financed through completion. A 135-patient randomised stage will require considerably more capital and time than the initial dose-escalation cohort.

The August milestone should therefore be interpreted narrowly but positively. CRISM has moved from manufacturing, regulatory approvals and site setup into actual recruitment. The next meaningful evidence is first dosing, followed eventually by safety and dose-selection data from those initial 12 patients.